@article{93880,
  keywords = {Buruli ulcer, Mycobacterium ulcerans, clinical trials, pharmacokinetics, pharmacology, treatment},
  author = {Van Der Werf T and Barogui Y and Converse P and Phillips R and Stienstra Y},
  title = {Pharmacologic management of  infection.},
  abstract = {<p>: Pharmacological treatment of Buruli ulcer ( infection; BU) is highly effective, as shown in two randomized trials in Africa.: We review BU drug treatment - in vitro, in vivo and clinical trials (PubMed: '(Buruli OR (Mycobacterium AND ulcerans)) AND (treatment OR therapy).' We also highlight the pathogenesis of  infection that is dominated by mycolactone, a secreted exotoxin, that causes skin and soft tissue necrosis, and impaired immune response and tissue repair. Healing is slow, due to the delayed wash-out of mycolactone. An array of repurposed tuberculosis and leprosy drugs appears effective in vitro and in animal models. In clinical trials and observational studies, only rifamycins (notably, rifampicin), macrolides (notably, clarithromycin), aminoglycosides (notably, streptomycin) and fluoroquinolones (notably, moxifloxacin, and ciprofloxacin) have been tested.: A combination of rifampicin and clarithromycin is highly effective but lesions still take a long time to heal. Novel drugs like telacebec have the potential to reduce treatment duration but this drug may remain unaffordable in low-resourced settings. Research should address ulcer treatment in general; essays to measure mycolactone over time hold promise to use as a readout for studies to compare drug treatment schedules for larger lesions of Buruli ulcer.</p>},
  year = {2020},
  journal = {Expert review of clinical pharmacology},
  pages = {1-11},
  month = {04/2020},
  issn = {1751-2441},
  url = {https://www.tandfonline.com/doi/full/10.1080/17512433.2020.1752663},
  doi = {10.1080/17512433.2020.1752663},
  language = {eng},
}